Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data presented at the ISTH 2025 Congress Jenni Thomas / Monday, June 23, 2025 0 65 Article rating: No rating Monday, June 23, 2025 Read more
Rivaroxaban versus enoxaparin in pediatric venous thromboembolism: experience in a hemostasis center Rivaroxaban versus enoxaparin in pediatric venous thromboembolism: experience in a hemostasis center Jenni Thomas / Sunday, June 22, 2025 0 407 Article rating: No rating Sunday, June 22, 2025 June 22, 2025 | Maria Landwehr Lardelli, M.D.; Vall d'Hebron University Hospital; Barcelona, Spain Read more
Essential role of VWF-aIIbß3 binding in thrombus stability in vessel injury Essential role of VWF-aIIbß3 binding in thrombus stability in vessel injury Jenni Thomas / Sunday, June 22, 2025 0 194 Article rating: No rating Sunday, June 22, 2025 June 22, 2025 | Qizhen Shi, M.D., Ph.D.; Medical College of Wisconsin and Versiti Blood Research Institute; Milwaukee, WI, U.S. Read more
Edoxaban for the treatment of pediatric venous thromboembolism: phase 3 randomized controlled trial Edoxaban for the treatment of pediatric venous thromboembolism: phase 3 randomized controlled trial Jenni Thomas / Sunday, June 22, 2025 0 230 Article rating: No rating Sunday, June 22, 2025 June 22, 2025 | Mihir Bhatt, M.D., M.Sc.; McMaster Children's Hospital, McMaster University; Hamilton, ON, Canada Read more
Clonal hematopoiesis of indeterminate potential in coronary disease patients: a 24-year follow-up Clonal hematopoiesis of indeterminate potential in coronary disease patients: a 24-year follow-up Jenni Thomas / Sunday, June 22, 2025 0 1189 Article rating: No rating Sunday, June 22, 2025 June 22, 2025 | Cynthia Carbonneau, M.D., Ph.D.; Centre Hospitalier Universitaire de Lille; Lille, France Read more